)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Panbela Therapeutics (PBLA) investor relations material
Panbela Therapeutics Q3 2024 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2024 earnings summary14 Nov, 2024
Executive summary
Secured up to $12M in strategic financing from Nant Capital, with $2.85M funded and $9.15M pending, supporting clinical and operational activities and enabling potential immunotherapy collaborations.
Advanced multiple clinical programs, including the pivotal Phase 3 ASPIRE trial in metastatic pancreatic cancer, and initiated a Phase I study in STK11 mutant NSCLC.
Achieved milestones such as FDA approval of Aflornithine for pediatric neuroblastoma and completion of enrollment in the Phase 3 PACE's trial for colorectal cancer prevention.
Delisted from Nasdaq in April 2024; shares now quoted on OTCQB, with relisting application pending.
CRO for ASPIRE trial terminated in August 2024 due to payment delays; company assumed direct trial management.
Financial highlights
Q3 2024 net loss was $7.2M ($1.48 per share), compared to $7.8M ($53.74 per share) in Q3 2023; nine-month net loss was $21.4M, up from $18.8M year-over-year.
R&D expenses for Q3 2024 were $6.0M–$6.1M, down from $6.7M in Q3 2023; G&A expenses were flat at $1.1M.
Cash as of September 30, 2024, was $142K–$0.1M, not including Nant Capital funding; current assets $5.2M, current liabilities $20.1M.
Cash used in operations for the nine months ended September 30, 2024, totaled $12.5M, down from $22.2M in the prior year.
Net loss per share for nine months ended September 30, 2024, was $(5.00), reflecting a higher share count.
Outlook and guidance
Full enrollment of the Phase 3 ASPIRE trial (~600 patients) expected by Q2 2025; interim analysis planned for Q1 2025 due to lower-than-expected event rates.
Data readout for the Phase 3 PACE's trial anticipated in the second half of 2026.
Interim analysis for the Type 1 diabetes trial expected next year; Phase 2 ovarian cancer and neoadjuvant pancreatic trials to open in early 2025.
Company expects to continue incurring substantial losses and negative cash flows as it advances clinical programs; additional capital is required to fund operations.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Panbela Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of cancer. The company's lead programs target pancreatic cancer and other gastrointestinal cancers, with an emphasis on inhibiting tumor growth and improving patient outcomes. Panbela’s approach involves advancing small-molecule therapeutics that address significant unmet medical needs in oncology, aiming to provide more effective treatment options for aggressive cancers. The company is headquartered in Waconia, Minnesota, USA, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage